Cargando…

Profile of selumetinib and its potential in the treatment of melanoma

The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dae Won, Patel, Sapna P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179759/ https://www.ncbi.nlm.nih.gov/pubmed/25278770 http://dx.doi.org/10.2147/OTT.S51596

Ejemplares similares

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
por: Lyons Rimmer, Jade, et al.
Publicado: (2020)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
por: Tian, Zhuowei, et al.
Publicado: (2023)

GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report
por: Patel, Sapna P., et al.
Publicado: (2016)

GNAQ mutation in a patient with metastatic mucosal melanoma
por: Kim, Chung-Young, et al.
Publicado: (2014)

Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment
por: Cebulla, Colleen M., et al.
Publicado: (2019)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

Novel treatment paradigms for metastatic uveal melanoma
por: Patel, Sapna P., et al.
Publicado: (2022)

Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice
por: Bosma, Nicholas A., et al.
Publicado: (2014)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs
por: Wächter, Sabine, et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma
por: Blackwood, Nigel, et al.
Publicado: (2023)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway
por: Li, Chen, et al.
Publicado: (2016)

Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo
por: Osum, Sara H, et al.
Publicado: (2021)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel, Ami B, et al.
Publicado: (2018)

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
por: Qin, Yong, et al.
Publicado: (2020)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
por: Novo, Sonia M., et al.
Publicado: (2017)

Profile of minocycline and its potential in the treatment of schizophrenia
por: Zhang, Lulu, et al.
Publicado: (2014)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015)

Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g5rgq7s9jff31otsr18kf1j6gl